Literature DB >> 6510892

A simplified radioimmunoassay for physiologically active angiotensin peptides [(1-8) octa- and (2-8) heptapeptides].

J Nussberger, R Re, G R Matsueda, E Haber.   

Abstract

The availability of a sensitive and highly specific rabbit antiserum and the development of a peptide-extraction method employing glass beads permitted the evolution of a rapid reliable radioimmunoassay that measures the sum of the concentration of angiotensin II and its active metabolite, angiotensin III. At a dilution of 1:32,000 the antiserum is capable of measuring 1 fmol (1 pg) of angiotensin II. Cross reactivities of this antiserum, taking angiotensin II as 1.0, are: angiotensin III, 0.75; angiotensin-(3-8) hexapeptide, 0.11; angiotensin I, 0.006; angiotensin-(1-14) tetradecapeptide, 0.0001. The recovery of angiotensin II added to hormone-free plasma was 73 +/- 2% [mean +/- standard deviation (SD), n = 20]. When 0.9 ml of plasma was extracted, the minimal concentration of angiotensin II and III that could be quantified was 4 fmol/ml. When larger volumes of plasma were extracted, sensitivity was enhanced. Plasma blanks were zero. Intra-assay variability was 7.6% SD and interassay variability was 11.7% SD. Angiotensin II and III concentration in venous plasma of normal volunteers on an ad libitum diet was 15 +/- 8 fmol/ml (mean +/- SD, range less than 4 to 35 fmol/ml). The plasma of a patient with primary aldosteronism had an unmeasurable value (less than 4 fmol/ml). Posture, converting enzyme inhibition, and renal artery stenosis resulted in expected changes of angiotensin concentration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6510892     DOI: 10.1055/s-2007-1014862

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  7 in total

1.  A comparison of the haemodynamic and hormonal effects of low and conventional dose cyclopenthiazide in normal volunteers.

Authors:  G E McVeigh; M McMaster; T Linton; E Whitehead; G D Johnston
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Epitope diversity of angiotensin II analysed with monoclonal antibodies.

Authors:  C Picard; P Ronco; P Moullier; J Yao; B Baudouin; M Geniteau Legendre; P Verroust
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

Review 3.  Enalapril: a review of human pharmacology.

Authors:  H J Gomez; V J Cirillo; J D Irvin
Journal:  Drugs       Date:  1985       Impact factor: 9.546

4.  The effects of cilazapril alone and in combination with frusemide in healthy subjects.

Authors:  G D Johnston; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

5.  The effect of acute and chronic captopril therapy on baroreflex function in man.

Authors:  G B Kondowe; A H Deering; J G Riddell; G D Johnston; D W Harron
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

Review 6.  Factors involved in the pathogenesis of hypertensive cardiovascular hypertrophy. A review.

Authors:  B Dahlöf
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Comparison of the acute renal and peripheral vascular responses to frusemide and bumetanide at low and high dose.

Authors:  A P Passmore; E M Whitehead; G D Johnston
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.